First-line doublet immunotherapy: Game changer or hype for patients with mesothelioma?

Saved in:
Bibliographic Details
Published in:Lung cancer (Amsterdam, Netherlands) Netherlands), 2024-08, Vol.194, p.107891, Article 107891
Main Authors: Douma, L.H., Baas, P., de Gooijer, C.J.
Format: Article
Language:English
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c243t-35146bca9e3de81f70269ca0d20d18e290b9ec27c7ac0be6ced6ee3cc71dff53
container_end_page
container_issue
container_start_page 107891
container_title Lung cancer (Amsterdam, Netherlands)
container_volume 194
creator Douma, L.H.
Baas, P.
de Gooijer, C.J.
description
doi_str_mv 10.1016/j.lungcan.2024.107891
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3082307409</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0169500224004252</els_id><sourcerecordid>3082307409</sourcerecordid><originalsourceid>FETCH-LOGICAL-c243t-35146bca9e3de81f70269ca0d20d18e290b9ec27c7ac0be6ced6ee3cc71dff53</originalsourceid><addsrcrecordid>eNqFkMtKAzEUhoMoWquPoGTpZupJ0k4mbkTEGwhuituQyZyxKXMzySh9e1Na3brKIXz_uXyEXDCYMWD59XrWjN2HNd2MA5-nP1kodkAmrJA8K4Tgh2SSOJUtAPgJOQ1hDcAkA3VMToQCpnKZT8j7o_MhZo3rkFb9WDYYqWvbsevjCr0ZNjf0ybRI7cp0H-hp7-lqMyCtUzGY6LCLgX67uKIthm2mcX1rbs_IUW2agOf7d0qWjw_L--fs9e3p5f7uNbN8LmImFmyel9YoFBUWrJbAc2UNVBwqViBXUCq0XFppLJSYW6xyRGGtZFVdL8SUXO3aDr7_HDFE3bpgsWlMh_0YtICCC5BzUAld7FDr-xA81nrwrjV-oxnorVG91nujemtU74ym3OV-xFi2WP2lfhUm4HYHYLrzy6HXwSYtaVXn0UZd9e6fET-l8Iug</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3082307409</pqid></control><display><type>article</type><title>First-line doublet immunotherapy: Game changer or hype for patients with mesothelioma?</title><source>ScienceDirect Journals</source><creator>Douma, L.H. ; Baas, P. ; de Gooijer, C.J.</creator><creatorcontrib>Douma, L.H. ; Baas, P. ; de Gooijer, C.J.</creatorcontrib><identifier>ISSN: 0169-5002</identifier><identifier>ISSN: 1872-8332</identifier><identifier>EISSN: 1872-8332</identifier><identifier>DOI: 10.1016/j.lungcan.2024.107891</identifier><identifier>PMID: 39019676</identifier><language>eng</language><publisher>Ireland: Elsevier B.V</publisher><ispartof>Lung cancer (Amsterdam, Netherlands), 2024-08, Vol.194, p.107891, Article 107891</ispartof><rights>2024</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c243t-35146bca9e3de81f70269ca0d20d18e290b9ec27c7ac0be6ced6ee3cc71dff53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39019676$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Douma, L.H.</creatorcontrib><creatorcontrib>Baas, P.</creatorcontrib><creatorcontrib>de Gooijer, C.J.</creatorcontrib><title>First-line doublet immunotherapy: Game changer or hype for patients with mesothelioma?</title><title>Lung cancer (Amsterdam, Netherlands)</title><addtitle>Lung Cancer</addtitle><issn>0169-5002</issn><issn>1872-8332</issn><issn>1872-8332</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNqFkMtKAzEUhoMoWquPoGTpZupJ0k4mbkTEGwhuituQyZyxKXMzySh9e1Na3brKIXz_uXyEXDCYMWD59XrWjN2HNd2MA5-nP1kodkAmrJA8K4Tgh2SSOJUtAPgJOQ1hDcAkA3VMToQCpnKZT8j7o_MhZo3rkFb9WDYYqWvbsevjCr0ZNjf0ybRI7cp0H-hp7-lqMyCtUzGY6LCLgX67uKIthm2mcX1rbs_IUW2agOf7d0qWjw_L--fs9e3p5f7uNbN8LmImFmyel9YoFBUWrJbAc2UNVBwqViBXUCq0XFppLJSYW6xyRGGtZFVdL8SUXO3aDr7_HDFE3bpgsWlMh_0YtICCC5BzUAld7FDr-xA81nrwrjV-oxnorVG91nujemtU74ym3OV-xFi2WP2lfhUm4HYHYLrzy6HXwSYtaVXn0UZd9e6fET-l8Iug</recordid><startdate>20240801</startdate><enddate>20240801</enddate><creator>Douma, L.H.</creator><creator>Baas, P.</creator><creator>de Gooijer, C.J.</creator><general>Elsevier B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20240801</creationdate><title>First-line doublet immunotherapy: Game changer or hype for patients with mesothelioma?</title><author>Douma, L.H. ; Baas, P. ; de Gooijer, C.J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c243t-35146bca9e3de81f70269ca0d20d18e290b9ec27c7ac0be6ced6ee3cc71dff53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Douma, L.H.</creatorcontrib><creatorcontrib>Baas, P.</creatorcontrib><creatorcontrib>de Gooijer, C.J.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Lung cancer (Amsterdam, Netherlands)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Douma, L.H.</au><au>Baas, P.</au><au>de Gooijer, C.J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>First-line doublet immunotherapy: Game changer or hype for patients with mesothelioma?</atitle><jtitle>Lung cancer (Amsterdam, Netherlands)</jtitle><addtitle>Lung Cancer</addtitle><date>2024-08-01</date><risdate>2024</risdate><volume>194</volume><spage>107891</spage><pages>107891-</pages><artnum>107891</artnum><issn>0169-5002</issn><issn>1872-8332</issn><eissn>1872-8332</eissn><cop>Ireland</cop><pub>Elsevier B.V</pub><pmid>39019676</pmid><doi>10.1016/j.lungcan.2024.107891</doi></addata></record>
fulltext fulltext
identifier ISSN: 0169-5002
ispartof Lung cancer (Amsterdam, Netherlands), 2024-08, Vol.194, p.107891, Article 107891
issn 0169-5002
1872-8332
1872-8332
language eng
recordid cdi_proquest_miscellaneous_3082307409
source ScienceDirect Journals
title First-line doublet immunotherapy: Game changer or hype for patients with mesothelioma?
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T23%3A59%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=First-line%20doublet%20immunotherapy:%20Game%20changer%20or%20hype%20for%20patients%20with%20mesothelioma?&rft.jtitle=Lung%20cancer%20(Amsterdam,%20Netherlands)&rft.au=Douma,%20L.H.&rft.date=2024-08-01&rft.volume=194&rft.spage=107891&rft.pages=107891-&rft.artnum=107891&rft.issn=0169-5002&rft.eissn=1872-8332&rft_id=info:doi/10.1016/j.lungcan.2024.107891&rft_dat=%3Cproquest_cross%3E3082307409%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c243t-35146bca9e3de81f70269ca0d20d18e290b9ec27c7ac0be6ced6ee3cc71dff53%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3082307409&rft_id=info:pmid/39019676&rfr_iscdi=true